Annals of Oncology Advance Access originally published online on January 29, 2009
Annals of Oncology 2009 20(5):874-878; doi:10.1093/annonc/mdn724
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
breast cancer |
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling
1 Unit of Screening and Follow-up for Hereditary and Familial Cancer, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples
2 Section of Genetic Oncology, Division of Surgical, Molecular and Ultrastructural Pathology, University of Pisa and Pisa University Hospital, Pisa, Italy
* Correspondence to: Dr M. Pensabene, Unit of Screening and Follow-up for Hereditary and Familial Cancer, Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, via Pansini 5, 80131 Naples, Italy. Tel: +39-0817462067; Fax: +39-0817462067; E-mail: matrod{at}libero.it
Background: Although most BRCA sequence variants are clearly deleterious and unequivocally pathogenetic, several are still classified as variants of unknown significance.
Patients and methods: We followed families undergoing oncogenetic counseling from risk identification to risk definition by genetic testing and risk management.
Results: We identified two germline mutations in the BRCA2 gene in a woman with breast and ovarian cancer. One sequence alteration was 859/G>A in exon 7 (V211I). The other second sequence alteration (IVS13-2A>T) affected the splicing site in intron 13. The latter alteration is not yet listed in the Breast Cancer Information Core database. RT–PCR resulted in transcription of a sequence lacking exon 7 and a subsequent anomalous stop codon in exon 9 thereby confirming altered messenger RNA (mRNA) maturation. Amplification of the mutation in intron 13 resulted in transcription of a sequence lacking exon 14 and an anomalous stop codon in exon 15 thereby confirming altered mRNA maturation. Both mutations led to a truncated BRCA2 protein in its carboxy-terminal region.
Conclusion: The two BRCA2 mutations identified affect mRNA splicing fidelity and play a pathogenetic role in breast and ovarian cancer.
Key words: BRCA2 germline mutation, cancer genetic counseling, hereditary breast cancer, intron mutations, unknown significance variation
Received for publication August 12, 2008. Revision received October 6, 2008. Accepted for publication October 29, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Diez and S. Gutierrez-Enriquez BRCA2 splice site mutations in an Italian breast/ovarian cancer family Ann. Onc., July 1, 2009; 20(7): 1285 - 1285. [Full Text] [PDF]
|
|
|
|
|
|
M. Colombo, C. B. Ripamonti, V. Pensotti, C. Foglia, B. Peissel, M. A. Pierotti, S. Manoukian, and P. Radice An unusual BRCA2 allele carrying two splice site mutations Ann. Onc., June 1, 2009; 20(6): 1143 - 1144. [Full Text] [PDF]
|
|